1. Introduction
===============

Phosphoinositides (PIs) and their derivatives are important for controlling a variety of vital cell functions including intracellular signaling cascades, regulated secretion, and cytoskeleton integrity \[[@r1]\]. The inositol containing phospholipids are abundant constituents of cell membranes of Archaea and all eukaryotes \[[@r2]\]. The importance of inositol signaling has been known for many years. However, the seminal discovery that ligation of cell surface receptors and PLC activity coupled to PI turnover and calcium release \[[@r3],[@r4]\] paved the way for the discovery of the secondary messengers InsP~3~ and diacylglycerol (DAG) and the downstream signaling cascades regulated by their generation and metabolism. InsP~3~ formation depends on phospholipase C (PLC) that is activated by a variety of specific cell surface receptors. PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP~2~), thus releasing soluble InsP~3~ \[[@r5],[@r6]\]. Pharmacological evidence supports InsP~3~ signaling in unicellular eukaryotes such as members of the phylum Apicomplexa, a diverse group that includes *Plasmodium*, *Toxoplasma* and *Cryptosporidium*. The mobilization of intracellular Ca^2+^ level by InsP~3~ in single cell pathogens was described in *Trypanosoma,* a Kinetoplastid member of the phylum Euglenozoa. Although the cell surface receptor mediated signaling cascades that lead to InsP~3~-dependent, and potentially DAG-dependent, signaling cascades have not been fully delineated, there is mounting evidence to suggest these pathways are operative in apicomplexans.

Interest in Ca^2+^ signaling in these parasites is motivated by a history of studies demonstrating the requirement of Ca^2+^ signaling for infection by apicomplexan parasites, as recently reviewed \[[@r7]\]. Elevation of intracellular calcium regulates secretion of adhesins from microneme organelles, as well as activating actin-myosin dependent motility. As described below, parasite pathways that recruit proteins sufficiently divergent from their mammalian hosts may be exploited for development of novel therapeutic interventions (Fig. **[1](#F1){ref-type="fig"}**).

Apicomplexans share many molecules pertinent to Ca^2+^ signaling with their closest relatives, the ciliates (phylum Ciliophora), despite these two groups being evolutionarily quite diverse \[[@r8]\]. Both groups are combined in the Alveolata, due to their endowment with subplasmalemmal flattened membranes, *i.e.* alveolar sacs in ciliates and inner membrane complex in apicomplexans. In ciliates, Ca^2+^ signaling mechanisms are known in some detail, including the molecular identity of intracellular Ca^2+^ channels involved in Ca^2+^ release from intracellular Ca^2+^ stores \[[@r9],[@r10]\]. In contrast, identifying Ca^2+^-channels in apicomplexans such as *Plasmodium* and *Toxoplasma* has proved a major challenge. However, the recent development of transgenic parasites expressing genetically encoded sensors for detection of Ca^2+^ in *P. falciparum* and *T. gondii* may reveal new aspects of Ca^2+^ signaling \[[@r11],[@r12]\] (Fig. **[2](#F2){ref-type="fig"}**).

2. Evidence of InsP~3~ turnover and InsP~3~-induced Ca^2+^ release in Apicomplexa
=================================================================================

Inositol and inositol phospholipids have been described in most Archaea and eukaryotes indicating this system developed in a common ancestor of the Archaea kingdom approximately 2 billion years ago \[[@r2],[@r13]\]. Inositol phospholipids (PI) are ubiquitous components of cell membranes, there is not a unique PI found only in apicomplexan. Table **[1](#T1){ref-type="table"}** shows some important PI specific enzymes that have been reported in Apicomplexa and other unicellular parasites. The pathway by which PI is generated appears conserved amongst all eukaryotes \[[@r13]\]. The genes encoding the enzyme phosphatidylinositol synthase that catalyzes the formation of phosphatidylinositol (PI) are well characterized in *P. falciparum* and *P. knowlesi* \[[@r14]\], *T. gondii* \[[@r15]\] and *T. brucei* \[[@r16]\]. Phosphatidylinositol transfer protein encoding genes are also present, suggesting the existence of systems responsible for transporting PI from the ER to the plasmamembrane \[[@r1]\]. In *Plasmodium*, Gardner *et al.*, 2002 \[[@r17]\] reported a gene encoding the enzyme phosphatidylinositol 4-kinase (PI4K) that catalyses the formation of phosphatidylinositol 4-phosphate (PIP) from phosphatidylinositol (PI). Thus, apicomplexans have the machinery to generate the precursor of InsP~3~. Table **[1](#T1){ref-type="table"}** summarizes known and putative proteins from the InsP~3~ pathway in model organisms and parasites. In mammalian systems the ability of InsP~3~ to act as a second messenger requires the enzymes to rapidly release InsP~3~ from PIP~2~, as well as the ability to reduce InsP~3~ levels to basal. Importantly, genetic evidence for phospholipase C enzymes can be found in all apicomplexans, except Sacrocysis (presumable due to a lack of genetic data), and Kinetoplastids (See  Table **[1](#T1){ref-type="table"}**). The presence of the archetypal PLCδ isoform in all genomes indicates the ability to generate InsP~3~ and DAG in unicellular parasites arising from a common ancestor. The enzymes involved in InsP~3~ metabolism are less well conserved. *Plasmodium falciparum* have an annotated inositol polyphosphate 5-phosphatase, an indication that they too can metabolize InsP~3~, to InsP~2~, whilst a specific inositol 1,4,5 trisphosphate 3-kinase has not been annotated. However, inositol polyphosphate kinase genes can be found in both *P. falciparum* and *T. gondii* genomes and may metabolize InsP~3~ to InsP~4~.

3. Pharmacological evidence for InsP~3~ signaling in apicomplexa
================================================================

Importantly, biochemical evidence to support PI turnover in apicomplexan parasites has also been reported in the literature. Despite the fact that mammalian RBCs have all the enzymes enabling the production of PIP~2~ from PI \[[@r18]\], a non-infected RBC has limited biosynthesis of PIP~2~ and other PIs \[[@r19]\]; in contrast, when a RBC is infected with *Plasmodium knowlesi; P falciparum*, \[[@r20]\] and *Babesia bovis* \[[@r21]\] PI turnover increases due parasite metabolism. Incubating red blood cells (RBC) infected with *P. falciparum* with radiolabeled myo-inositol \[[@r22]\] results in the biosynthesis of PI, PIP and PIP~2~. Moreover, treatment with the Ca^2+^ ionophore, ionomycin, caused an increase in inositol phosphate production with Ins1,4,5P~3~ levels being the highest. The increase of intracellular Ca^2+^ promoted by ionomycin presumably activates the Ca^2+^ sensitive PLC \[[@r23]\] to cleave PIP~2~, thus generating InsP~3~. Martin *et al.* \[[@r24]\] demonstrated the formation of InsP~3~ and diacylglycerol (DAG) during exflagellation of *P. falciparum* gametocytes, an important event in the sexual cycle that takes place in the *Anopheles* mosquitos. Fang *et al.,*\[[@r25]\] identified a PI-PLCδ in *T. gondii* that cleaves PIP~2~. Whilst recent bioinformatic approaches have failed to identify intracellular Ca^2+^ release channels such as IP~3~Rs and Ryanodine receptors (RyRs) within the genomes of apicomplexans \[[@r7], [@r26]-[@r28]\], a large body of pharmacological evidence suggests that a Ca^2+^ release channel sensitive to InsP~3~ does indeed exist in these species. Prompted by evidence that malaria parasites maintain intracellular Ca^2+^ stores, Passos *et al.* \[[@r29]\] published the first work demonstrating InsP~3~ mobilized Ca^2+^ from an intracellular store in *P. chabaudi* using a permeabilized cell system. The response was blocked by heparin (an inhibitor of InsP~3~Rs) providing pharmacological evidence for an InsP~3~ dependent Ca^2+^ channel in *P. chabaudi*. Similarly, treatment of microsome preparations from *T. gondii* tachyzoites with InsP~3~ initiated Ca^2+^ release which could be fully blocked by pharmacological inhibitors of InsP~3~Rs (Xestospongin C and heparin) \[[@r30]\].

Inhibitors of the InsP~3~ signaling pathway, including agents that block InsP~3~R, such as heparin, xestospogin C and 2-aminoethoxydiphenyl borinate (2-APB), as well as inhibitors of PLC, such as U73122, have also been used to study Ca^2+^ signaling in Apicomplexa \[[@r31]\]. In *T. gondii*, the release of adhesins that mediate parasite attachment to host cells is an event regulated by Ca^2+^-mediated microneme secretion \[[@r32],[@r33]\]. Lovett*et al.*, (2002) also reported that *T. gondii* mobilizes Ca^2+^ when exposed to ryanodine or caffeine, both RyR ligands \[[@r34]\]. Addition of xestospongin C inhibited the caffeine- or ethanol-induced increase of intracellular Ca^2+^, thus preventing microneme secretion in *T. gondii* \[[@r35]\], and suggesting a role for InsP~3~R. In *Paramecium* this pathway controls stimulated trichocyst exocytosis, as found by energy-dispersive X-ray microanalysis and fluorochrome analysis \[[@r36]\], via activation of RyR-type Ca^2+^ release channels in alveolar sacs \[[@r10],[@r37]\]. RyRs share common features and an evolutionary history with InsP~3~Rs \[[@r9],[@r38],[@r39]\], yet RyRs are activated by the intracellular messenger cADPR (cyclic ADP-ribose) \[[@r40]\]. In fact, cADPR has been shown to activate Ca^2+^ signaling pathways in *T. gondii* and *P. falciparum* \[[@r30],[@r41]\].

In malaria melatonin dependent signaling via calcium is well established \[[@r29],[@r42],[@r43]\] enabling the investigation of a natural ligand to induce intracellular signaling. Hotta *et al.*, \[[@r42]\] reported that intracellular Ca^2+^ mobilization induced by melatonin in *P. falciparum* and *P. chabaudi* is abolished by the PLC inhibitor U73122, but not by its inactive analogue, indicating that melatonin may activate signaling via PLC/InsP~3~. Enomoto *et al.*, \[[@r44]\] blocked spontaneous Ca^2+^ mobilization in the ring and trophozoite forms of intraerythrocytic stage of *P. falciparum* using the InsP~3~R inhibitor, 2-APB \[[@r45]\]. The presence of 2-APB during intraerythrocytic development of *P. falciparum* compromised the asexual replication of this parasite suggesting that blocking the InsP~3~R can be a potential target for antimalarial treatment. Raabe *et al.*, \[[@r46]\] investigated the role of PLP~2~/PLC/InsP~3~ during *P. berghei* gametocyte exflagellation induced by xanthurenic acid (XA), a small metabolic intermediate found in *Anopheles* mosquito gut. Under XA stimulus, addition of the PLC inhibitor U73122 inhibits Ca^2+^ mobilization in this model. Together this work suggested a vital role of the InsP~3~/PLC signaling pathway at different points during the *Plasmodium* life cycle, and the important nature of this pathway suggests it may contain potential antimalarial targets expressed during all life cycle phases.

Evidence for a ryanodine sensitive store in *T. gondii* \[[@r35]\] motivated Raabe *et al.*, \[[@r46]\] to investigate the role of Ca^2+^ release via the RyR in *P. berghei* during gametocyte maturation. In the presence of RyR inhibitors, dantrolene and ruthenium red (RR), XA mediated Ca^2+^ increases were attenuated. Remarkably, RR treatment decreased InsP~3~ levels and dantrolene inhibited gametocyte maturation during XA stimulation. These data also suggest the existence of ryanodine sensitive channels in *P. berghei*. The development of cell permeant caged Ins1,4,5P~3~,\[[@r47]\], enabled the investigation of InsP~3~ dependent calcium signaling without compromising membrane integrity. With this tool, Alves *et al.* \[[@r43]\] reported that *P. falciparum* trophozoites within intact RBCs release Ca^2+^ from thapsigargin-sensitive stores due to liberation of caged Ins1,4,5P~3~. This observation was the first demonstration of a Ca^2+^-increase induced by exogenous InsP~3~ under physiological conditions in Apicomplexa. Furthermore, the authors reported an increase of InsP~3~ in infected RBC treated with melatonin. These data further support the concept of PIP~2~ hydrolysis to InsP~3~ as a signaling pathway activated by melatonin in *P. falciparum,* as reported previously \[[@r42],[@r48]\].

Mossaad *et al.* \[[@r49]\] first reported a complete reversal of chloroquine resistance in malaria parasites after treatment with 2-APB *in vitro* and *in vivo*, and this effect was justified by disturbance of Ca^2+^ homeostasis in the parasite cell. This result showed that 2-APB and other related compounds that block the InsP~3~ pathway might be promising candidates in the search for new-resistance reversing agents that aid in treatment of the disease.

Beraldo *et al.* \[[@r50]\] showed that increase in cytosolic Ca^2+^ concentration in melatonin induced *P. falciparum* is abolished with the use of 2-APB, U73122 (PLC inhibitor) and luzindole (a melatonin antagonist). In the same work, capacitative calcium entry was also reported in malaria parasites.

Since then, other pharmacological agents have further been applied to investigate this pathway. It should be noted that most drugs used to interfere with signaling in protozoa are used solely on the basis of effects observed in mammalian cells \[[@r31]\], and all these drugs have potential off target effects. Despite this caveat, the combined evidence of a number of studies suggest the presence of an InsP~3~R and/or RYR calcium release channels in *Plasmodia* and *Toxoplasma*.

4. InsP~3~Rs and RyRs in Protozoans
===================================

The history of InsP~3~R discovery and the impact of this receptor on mammalian cell signaling has been previously reviewed \[[@r51]\]. Knowledge of receptor sequences and functional proprieties in mammals, together with increasing information and access to genome databases for different organisms, made bioinformatics tools such as BLAST searches a major strategy to identify orthologs to putative InsP~3~R and RyRs in metazoans.

Until recently no information about such channels has been available from protozoa. After successful identification of InsP~3~Rs and RyR-like proteins \[[@r9],[@r37],[@r52]\] in the ciliated protozoan, *Paramecium,* partial sequences suggested the occurrence of InsP~3~Rs in several protozoan phyla, including trypanosomatids \[[@r37],[@r39]\]. Similarity with established InsP~3~Rs is often scattered throughout the protein, with highest similarity in the carboxy-terminal region containing the pore domain. Prole and Taylor \[[@r53]\] also used conserved regions of InsP~3~R and RyR, specifically the amino-terminal RIH (RyR and InsP~3~R homology) domain and the N-terminal InsP~3~-binding domain, to successfully identify candidates for InsP~3~R in *T. cruzi* and *T. brucei*. Such work supported the identification of an InsP~3~R-type protein in *T. cruzi* \[[@r54],[@r55]\] and *T. brucei* \[[@r56]\]. Hashimoto *et al.* \[[@r54]\] demonstrated that *TcInsP~3~R* is essential for *T. cruzi* epimastigote survival, contributes to parasite invasiveness in mammalian cells, mediates Ca^2+^ release in trypomastigotes upon attachment to host cells, modulates parasite development and contributes to parasite virulence. These findings are consistent with previous evidence for a InsP~3~/DAG pathway in *T. cruzi* (*49*) and *T brucei* \[[@r47]\].

The identification of an InsP~3~R candidate in apicomplexan parasites is a much more challenging task. When the same sequences of mammalian InsP~3~Rs were used for BLAST searches, no InsP~3~R orthologs were identified for *Plasmodium*, *Toxoplasma, Cryptosporidium* or *Babesia* species \[[@r53]\]. Previously, Naganume *et al.* \[[@r58]\], using a collection of Ca^2+^-associated protein orthologs to identify proteins participating in Ca^2+^ signaling, were also unable to find either any orthologs of InsP~3~Rs, or of protein kinase C (PKC), a classic target for DAG activation \[[@r59]\]. Ladenburger *et al.,* (2009) \[[@r37]\] were also unable to detect any InsP~3~R or RyR orthologs in genomes of apicomplexans, in contrast to ciliates where they are readily found.

Recently, it was reported that, when *TcInsP~3~R* expression is decreased by two thirds compared to wildtype, the invasion of trypomastigotes of *T. cruzi* is blocked, indicating *TcInsP~3~R* as a potential therapeutic target \[[@r60]\]. After treatment of trypomastigotes with specific antisense oligonucleotides of *TcInsP~3~R*, a reduction in infectivity, thus suggesting that the suppression of transcription of this gene led to reduced levels of *TcInsP~3~R* protein. In Chagas disease, Ca^2+^ signaling mediated by InsP~3~R plays a key role in multiple parasite differentiation steps \[[@r61]\]. A therapeutic approach using antisense transcripts is particularly feasible in the acute phase of infection in which trypomastigotes predominate in the bloodstream. It is possible that a treatment with antisense transcripts is effective in preventing the development of the disease by blocking the proliferation of trypomastigotes by inhibition of production of TcInsP~3~R \[[@r62]\].

The presence of dense mitochondria in *T. cruzi* with nonfunctional InsP~3~R provides new insights for the contribution of InsP~3~Rs to organelle integrity and the fact that 2-APB does not completely inhibit the development of trypomastigotes \[[@r63]\] suggest structural difference to mammalian InsP~3~Rs \[[@r64]\]. On the other hand, at high concentrations, 2-APB might influence functions of proteins other than InsP~3~Rs.

5. Lessons from other systems
=============================

Clues about the composition of Ca^2+^ signaling pathways in apicomplexans can be drawn from their closest ancestral group, free living ciliates. It is estimated that ciliates originated between \~800 and 850 million years \[[@r65],[@r66]\]. Apicomplexa are assumed to have arisen \~550, and the genus *Plasmodium* \~400 million years ago \[[@r65]\]. These events occurred much before Apicomplexa became parasites of vertebrates and then of mammalian species, which occurred only \~13 million years ago \[[@r67]\]. *Paramecium tetraurelia* contains several genes encoding InsP~3~Rs and RyR-like channels that have been identified at a genomic and proteomic level \[[@r9],[@r37],[@r52]\]. Considering the finding of InsP~3~Rs and of RyR-like channels in *Paramecium* \[[@r10]\], the argument that the old age of some phyla may explain the failure to detect Ca^2+^ release channels in apicomplexans appears unlikely.

The lack of conservation at the gene level, suggests that InsP~3~R in apicomplexans may diverge significantly from mammalian channels and those found in ciliates; one may ask whether they adopted a different, distinct protein or a complex of proteins for InsP~3~R function. If this is the case, successful identification of InsP~3~R in apicomplexans may require a different strategy focused on biochemical and physiological criteria. Specifically one should consider that any Ca^2+^ release channel requires a pore domain with six transmembrane stretches in InsP~3~Rs and RyRs, from ciliates to humans, and a rather conserved, though slightly variable selectivity filter \[[@r10]\].

Currently the lack of identified Ca^2+^ release channels in Apicomplexa leaves a significant gap in our understanding of PI and calcium signaling mechanisms. There are clear physiological effects of stimulating production of InsP~3~, and of inhibiting putative channels, and yet the molecular machinery in Apicomplexa is clearly diverse from other cells. Ultrastructurally the inner membrane complex of Apicomplexa looks very much like the alveolar sacs of ciliates; however, whereas the sacs of ciliates are well established Ca^2+^ stores \[[@r36]\], they appear largely independent of such function in Apicomplexa \[[@r8]\]. The third enigma is the presence of well defined InsP~3~R- and RyR-type Ca^2+^ release channels in ciliates \[[@r9],[@r37],[@r52]\], in contrast to their absence in their closest relatives, the Apicomplexa \[[@r68],[@r69]\].

Similar to apicomplexans, plant genomes lack recognizable InsP~3~Rs in despite of evidence for an InsP~3~ signaling pathway \[[@r70]\]. Despite responding to InsP~3~ to regulate Ca^2+^ increases, land plants typically lack an InsP~3~R or RyR, leading to the suggestion that these channels were animal-specific, and perhaps evolved during the vertebrate lineage \[[@r70]\]. However, recent evidence from green algae *Chlamydomonas* indicates that chlorophyte plants contain InsP~3~R, suggesting they were present in the ancestral eukaryotes prior to the plant-animal split \[[@r71]\]. Why InsP~3~R channels appear to have been lost in land plants remains a mystery, but it is intriguing to consider that like apicomplexans, they may have evolved different mechanism to release internal Ca^2+^ stores in response to InsP~3~.

Conclusion
==========

Differences in Ca^2+^ signaling between parasites and their hosts may present unique targets for developing interventions. For example, McNamara *et al.*, 2013 \[[@r72]\] reported PI4K as a target of imidazopyrazine, a class of new antimalarial drug that inhibits all stages of malaria parasite infection of the vertebrate host and also prevents transmission by mosquitos to a murine malaria model. Additionally, as mentioned above, agents that disrupt InsP~3~R channels such as 2-ABP block malaria growth *in vitro* \[[@r44]\]. Given the apparent divergent mechanism by which InsP~3~ is sensed in parasites, identification of the molecular basis for this pathway might also identify novel targets for intervention.

The pharmacological literature and functional studies with exogenous InsP~3~ discussed herein seem to support the occurrence of InsP~3~R-type Ca^2+^-channels in ciliates, trypanosomatids and apicomplexans. InsP~3~R is the major missing piece of the PI signaling puzzle in Apicomplexa. Although InsP~3~R have been found in ciliates and tryponosomatids, the lack of ^3^H-InsP~3~ binding assays in parallel to a vast unknown protein function in apicomplexans genome has hampered the identification of potential candidates for InsP~3~R. Although identification of these channels will certainly not be an easy task, it will be a rewarding engagement for groups willing to accept the challenge.
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![Schematic representation of the myo-inositol 1,4,5-triphosphate (InsP~3~) turnover and its function in intracellular Ca^2+^ release. Step 1: Inositol incorporation into CDP-DAG (CDP = cytidine diphosphate DAG = diacylglycerol) catalyzed by phosphatidylinositol synthase generating phosphatidylinositol (PI). Step 2: Phosphorylation of PI by phosphatidylinositol 4-kinase forming phosphatidylinositol 4-phosphate (PIP). Step 3: Phosphorylation of PIP by phosphatidylinositol 4-phosphate 5-kinase forming phosphatidyl 4,5-bisphosphate (PIP~2~). Step 4: PIP~2~ is cleaved by phospholipase C (PLC) generating a soluble molecule, inositol 1,4,5-trisphosphate (InsP~3~), that is capable to bind to a InsP~3~ receptor (InsP~3~R) present in the membranes of intracellular compartments. InsP~3~ binding temporarily opens the InsP~3~R that acts as a Ca^2+^-release channel, so that Ca^2+^ can flow into the cytoplasm. The insoluble fraction formed by cleavage of PIP~2~ is diacylglycerol (DAG). Step 5: InsP~3~ is dephosphorylated by inositolpolyphosphate 5-phosphatase forming inositol 1,4-bisphosphate (InsP~2~). Step 6: InsP~2~ is desphosphorylated by inositol polyphosphate 1-phosphatase generating inositol 1-monophosphate (InsP). Step 7: Dephosphorylation of InsP to inositol by inositol monophosphatase. Step 8: phosphorylation of InsP~3~ by inositol 1,4,5-trisphosphate 3-kinase generating inositol 1,3,4,5-tetrakisphosphate (InsP~4~).](CTMC-17-2158_F1){#F1}

![Phylogenetic tree showing evolutionary relationships among organisms discussed in this review.](CTMC-17-2158_F2){#F2}

###### 

Occurrence of proteins important for the InsP~3~ signaling pathway in some model organisms. The corresponding genes were searched for in the databases of *Plasmodium*, *Toxoplasma*, *Homo sapiens*, *Trypanosoma* and *Paramecium* (PlasmoDB, ToxoDB, PDB/NCBI, TriTrypDB and ParameciumDB, respectively). Phospholipase C of *Paramecium tetraurelia* is described in Klöppel *et al.*, 2009 \[[@r27]\]. (1) Putative protein; (2) -like proteins; (3) encoded by pseudogene; (4) Leondaritis *et al.* (2013) \[[@r28]\], described 62 highly homologous phosphoinositide kinases genes; \*genes that could not be found in databases.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                        **Phosphatidyl**\                      **Phosphatidyl**\                                           **Phospholipase C**                    **Inositol**\            **Inositol 1,4,5-Trisphosphate**\   **Inositol Triphosphate Receptor**
                                        **Inositol 4-kinase**                  **Inositol 4-phosphate 5-kinase**                                                                  **Polyphosphate**\       **3-kinase**                        
                                                                                                                                                                                  **5-phosphatase**                                            
  ------------------------------------- -------------------------------------- ----------------------------------------------------------- -------------------------------------- ------------------------ ----------------------------------- ------------------------------------
  ***Plasmodium falciparum* 3D7**       PF3D7_0509800; PF3D7_0419900^(1)^      PF3D7_0110600; PF3D7_1129600^(1)^                           PF3D7_1013500                          PF3D7_1354200^(1)^       \*                                  \*

  ***Toxoplasma gondii* ME49**          TGME49_328200                          TGME49_245730                                               TGME49_248830                          \*                       \*                                  \*

  ***Homo sapiens***                    AAA56839.1; BAA21661.1                 CAD99242.1                                                  AAA60112.1; BAA07688.1                 CAA74743.1; CAA67071.1   AAH26331.1; CAC40650.1              NP_002214.2

  ***Leishmania major* Friedlin**       LmjF.34.3590^(1)^; LmjF.29.1450^(1)^   LmjF.36.0370^(2)^; LmjF.34.3090^(2)^; LmjF.35.0560^(1,2)^   LmjF.30.2950^(2)^; LmjF.22.1680^(1)^   \*                       \*                                  LmjF.16.0280^(1)^

  ***Trypanossoma brucei* gambiense**   Tbg972.4.970^(1)^                      Tbg972.10.4830^(1)^                                         Tbg972.11.6720^(1)^                    \*                       \*                                  Tbg972.8.2330^(1)^

  ***Trypanossoma cruzi* CL Brener**    TcCLB.505987.70^(1)^                   TcCLB.510289.30^(1)^; TcCLB.511001.70^(1)^                  TcCLB.508039.90^(3)^                   \*                       \*                                  BAM68694.1

  ***Paramecium tetraurelia***          XP_001346932.1                         XP_001347030.1; XP_001347013.1                              XP_001432600.1;\                       \*                       ^(4)^                               PTMB.445c
                                                                                                                                           XP_001426835.1                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
